{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:07:32Z","timestamp":1789650452630,"version":"4.0.0"},"reference-count":84,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annalsjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Medicine and Surgery"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.amsu.2018.01.002","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T09:27:13Z","timestamp":1517390833000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Skeletal metastasis in renal cell carcinoma: A review"],"prefix":"10.1097","volume":"27","author":[{"given":"Masood","family":"Umer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Mohib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Atif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Nazim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.amsu.2018.01.002_bib1","series-title":"Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5","author":"Ferlay","year":"2004"},{"issue":"4","key":"10.1016\/j.amsu.2018.01.002_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1464-410X.2002.02910.x","article-title":"Prognostic significance of the mode of detection in renal tumours","volume":"90","author":"Patard","year":"2002","journal-title":"BJU Int."},{"issue":"2","key":"10.1016\/j.amsu.2018.01.002_bib3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0302-2838(03)00216-1","article-title":"Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma","volume":"44","author":"Patard","year":"2003","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0022-5347(17)54359-1","article-title":"Renal cell carcinoma: long-term survival and late recurrence","volume":"126","author":"McNichols","year":"1981","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.amsu.2018.01.002_bib5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.urology.2010.07.462","article-title":"Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer","volume":"77","author":"Miyao","year":"2011","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.amsu.2018.01.002_bib6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0094-0143(21)00636-4","article-title":"Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites","volume":"21","author":"Kozlowski","year":"1994","journal-title":"The Urol. Clin. North Am."},{"issue":"11","key":"10.1016\/j.amsu.2018.01.002_bib7","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ncponc0634","article-title":"Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib","volume":"3","author":"Rini","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"18","key":"10.1016\/j.amsu.2018.01.002_bib8","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-040031","article-title":"Prognostic factors for survival of patients with stage IV renal cell carcinoma","volume":"10","author":"Motzer","year":"2004","journal-title":"Clin. Canc. Res."},{"issue":"4","key":"10.1016\/j.amsu.2018.01.002_bib9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/annonc\/mdq554","article-title":"Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib","volume":"22","author":"Beuselinck","year":"2010","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.amsu.2018.01.002_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/annonc\/mdq342","article-title":"Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma","volume":"22","author":"Patil","year":"2010","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.amsu.2018.01.002_bib11","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0090-4295(81)90455-6","article-title":"Osseous metastases secondary to renal cell carcinoma","volume":"18","author":"Swanson","year":"1981","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13046-015-0122-0","article-title":"Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?","volume":"34","author":"Santoni","year":"2015","journal-title":"J. Exp. Clin. Canc. Res."},{"issue":"5","key":"10.1016\/j.amsu.2018.01.002_bib13","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.juro.2010.12.037","article-title":"Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors?","volume":"185","author":"Kume","year":"2011","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.2000.15.1.2","article-title":"The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption","volume":"15","author":"Hofbauer","year":"2000","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.amsu.2018.01.002_bib15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/path.2567","article-title":"Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas","volume":"218","author":"Mikami","year":"2009","journal-title":"J. Pathol."},{"issue":"27","key":"10.1016\/j.amsu.2018.01.002_bib16","doi-asserted-by":"crossref","first-page":"12665","DOI":"10.1016\/S0021-9258(18)67143-1","article-title":"Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose","volume":"261","author":"Hauschka","year":"1986","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1359\/jbmr.061005","article-title":"TGF-beta promotes the establishment of renal cell carcinoma bone metastasis","volume":"22","author":"Kominsky","year":"2007","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"3\u20134","key":"10.1016\/j.amsu.2018.01.002_bib18","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10555-007-9090-y","article-title":"Renal cell carcinoma bone metastasis\u2013elucidating the molecular targets","volume":"26","author":"Weber","year":"2007","journal-title":"Canc. Metastasis Rev."},{"key":"10.1016\/j.amsu.2018.01.002_bib19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1476-4598-13-42","article-title":"High calcium concentration in bones promotes bone metastasis in renal cell carcinomas expressing calcium-sensing receptor","volume":"13","author":"Joeckel","year":"2014","journal-title":"Mol. Canc."},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1158\/0008-5472.CAN-03-1968","article-title":"Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene","volume":"64","author":"Massfelder","year":"2004","journal-title":"Canc. Res."},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/carcin\/bgi203","article-title":"Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo","volume":"27","author":"Talon","year":"2006","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.amsu.2018.01.002_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jbo.2015.07.001","article-title":"Increased insulin mRNA binding Protein-3 expression correlates with vascular enhancement of renal cell carcinoma by intravenous contrast-CT and is associated with bone metastasis","volume":"4","author":"Xie","year":"2015","journal-title":"J. Bone Oncol."},{"issue":"2","key":"10.1016\/j.amsu.2018.01.002_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089880","article-title":"Cadherin-11 in renal cell carcinoma bone metastasis","volume":"9","author":"Satcher","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.amsu.2018.01.002_bib24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.juro.2015.01.079","article-title":"Bone metastasis in renal cell carcinoma is preprogrammed in the primary tumor and caused by AKT and integrin alpha5 signaling","volume":"194","author":"Haber","year":"2015","journal-title":"J. Urol."},{"issue":"10","key":"10.1016\/j.amsu.2018.01.002_bib25","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.7150\/ijbs.5106","article-title":"Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas","volume":"8","author":"Wotschofsky","year":"2012","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s13577-014-0101-3","article-title":"Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis","volume":"28","author":"Mukai","year":"2015","journal-title":"Hum. Cell"},{"key":"10.1016\/j.amsu.2018.01.002_bib27","article-title":"Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer","author":"Sohaib","year":"2014","journal-title":"British J. Radiol."},{"issue":"4","key":"10.1016\/j.amsu.2018.01.002_bib28","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ctrv.2011.06.011","article-title":"Skeletal metastasis in renal cell carcinoma: current and future management options","volume":"38","author":"Wood","year":"2012","journal-title":"Canc. Treat Rev."},{"issue":"2","key":"10.1016\/j.amsu.2018.01.002_bib29","first-page":"379","article-title":"The skeletal metastatic complications of renal cell carcinoma","volume":"19","author":"Zekri","year":"2001","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.amsu.2018.01.002_bib30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2165\/00003495-200868040-00010","article-title":"Zoledronic acid : a review of its use in the management of bone metastases of malignancy","volume":"68","author":"Dhillon","year":"2008","journal-title":"Drugs"},{"issue":"16","key":"10.1016\/j.amsu.2018.01.002_bib31","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the zoledronic acid lung cancer and other solid tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.amsu.2018.01.002_bib32","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.amsu.2018.01.002_bib33","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J. Nat. Cancer Inst."},{"issue":"12","key":"10.1016\/j.amsu.2018.01.002_bib34","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.amsu.2018.01.002_bib35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ncponc1323","article-title":"Effect of bisphosphonates on pain and quality of life in patients with bone metastases","volume":"6","author":"Costa","year":"2009","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"2","key":"10.1016\/j.amsu.2018.01.002_bib36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/00365590802475904","article-title":"Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines","volume":"43","author":"Ull\u00e9n","year":"2009","journal-title":"Scand. J. Urol. Nephrol."},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clgc.2014.07.002","article-title":"Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial","volume":"13","author":"Broom","year":"2015","journal-title":"Clin. Genitourin. Canc."},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/bjc.2013.272","article-title":"Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: the TUGAMO study","volume":"109","author":"Alcaraz","year":"2013","journal-title":"British J. cancer"},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00345-013-1059-6","article-title":"Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?","volume":"32","author":"Keizman","year":"2014","journal-title":"World J. Urol."},{"issue":"3","key":"10.1016\/j.amsu.2018.01.002_bib40","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2014.02.040","article-title":"Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma","volume":"66","author":"McKay","year":"2014","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.amsu.2018.01.002_bib41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bone.2007.05.002","article-title":"Acute phase response and mineral status following low dose intravenous zoledronic acid in children","volume":"41","author":"Munns","year":"2007","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.amsu.2018.01.002_bib42","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/annonc\/mdn788","article-title":"Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?","volume":"20","author":"Ayllon","year":"2009","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"5","key":"10.1016\/j.amsu.2018.01.002_bib43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10147-008-0868-x","article-title":"Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient","volume":"14","author":"Hasegawa","year":"2009","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.amsu.2018.01.002_bib45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2014may 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.amsu.2018.01.002_bib46","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.amsu.2018.01.002_bib47","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. cancer (Oxford, England : 1990)"},{"issue":"35","key":"10.1016\/j.amsu.2018.01.002_bib48","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.amsu.2018.01.002_bib49","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.amsu.2018.01.002_bib50","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.eururo.2006.01.016","article-title":"Understanding the importance of smart drugs in renal cell carcinoma","volume":"49","author":"Patard","year":"2006","journal-title":"Eur. Urol."},{"key":"10.1016\/j.amsu.2018.01.002_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001425.pub2","article-title":"Immunotherapy for advanced renal cell cancer","volume":"1","author":"Coppin","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.amsu.2018.01.002_bib52","first-page":"453","article-title":"Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways","volume":"1","author":"Jiang","year":"2003","journal-title":"Mol. Canc. Res."},{"issue":"22","key":"10.1016\/j.amsu.2018.01.002_bib53","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.amsu.2018.01.002_bib54","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ijc.26034","article-title":"Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function","volume":"130","author":"Maita","year":"2012","journal-title":"Int. J. Canc."},{"issue":"3","key":"10.1016\/j.amsu.2018.01.002_bib55","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s12032-009-9327-4","article-title":"Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature","volume":"27","author":"Karaca","year":"2010","journal-title":"Med. Oncol."},{"issue":"3","key":"10.1016\/j.amsu.2018.01.002_bib56","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00432-009-0664-7","article-title":"Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases","volume":"136","author":"\u017bo\u0142nierek","year":"2010","journal-title":"J. Canc. Res. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.amsu.2018.01.002_bib57","doi-asserted-by":"crossref","first-page":"26879","DOI":"10.18632\/oncotarget.8568","article-title":"Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of Sunitinib","volume":"7","author":"Lu","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.amsu.2018.01.002_bib58","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.amsu.2018.01.002_bib59","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9605","key":"10.1016\/j.amsu.2018.01.002_bib60","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2008","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.amsu.2018.01.002_bib61","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"9637","key":"10.1016\/j.amsu.2018.01.002_bib62","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.amsu.2018.01.002_bib63","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2214\/AJR.09.4110","article-title":"Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know","volume":"195","author":"Nishino","year":"2010","journal-title":"Am. J. Roentgenol."},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib64","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12253-009-9184-7","article-title":"Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases","volume":"16","author":"Szendr\u0151i","year":"2010","journal-title":"Pathol. Oncol. Res."},{"issue":"15","key":"10.1016\/j.amsu.2018.01.002_bib65","first-page":"4233","article-title":"Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis","volume":"54","author":"Takahashi","year":"1994","journal-title":"Canc. Res."},{"issue":"4","key":"10.1016\/j.amsu.2018.01.002_bib66","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s003300050969","article-title":"Preoperative embolization of bone metastases from renal cell carcinoma","volume":"10","author":"Chatziioannou","year":"2000","journal-title":"Eur. Radiol."},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib67","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000474416","article-title":"Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases","volume":"31","author":"Giberti","year":"1997","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.amsu.2018.01.002_bib68","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1200\/JCO.1998.16.6.2261","article-title":"Resection of metastatic renal cell carcinoma","volume":"16","author":"Kavolius","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.amsu.2018.01.002_bib69","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0936-6555(05)81063-5","article-title":"The value of internal fixation and radiotherapy in the management of upper and lower limb bone metastases","volume":"4","author":"Hardman","year":"1992","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.amsu.2018.01.002_bib70","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1097\/01.blo.0000093842.72468.73","article-title":"Critical evaluation of Mirels' rating system for impending pathologic fractures","volume":"415","author":"Damron","year":"2003","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.amsu.2018.01.002_bib71","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/01.blo.0000093045.56370.dd","article-title":"The classic: metastatic disease in long bones a proposed scoring system for diagnosing impending pathologic fractures","volume":"415","author":"Mirels","year":"2003","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.amsu.2018.01.002_bib72","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1097\/01.blo.0000093849.72468.82","article-title":"Metastatic disease of the femur: surgical treatment","volume":"415","author":"Ward","year":"2003","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"4","key":"10.1016\/j.amsu.2018.01.002_bib73","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0022-5347(17)60797-3","article-title":"Cryosurgery in the treatment of solitary or multiple bone metastases from renal cell carcinoma","volume":"108","author":"Marcove","year":"1972","journal-title":"J. Urol."},{"issue":"6","key":"10.1016\/j.amsu.2018.01.002_bib74","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2106\/JBJS.H.00175","article-title":"Surgical management of metastatic bone disease","volume":"91","author":"Bickels","year":"2009","journal-title":"JBJS"},{"issue":"7","key":"10.1016\/j.amsu.2018.01.002_bib75","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00005131-200408000-00013","article-title":"Management of pathologic fractures of the proximal femur: state of the art","volume":"18","author":"Jacofsky","year":"2004","journal-title":"J. Orthop. Trauma"},{"issue":"2","key":"10.1016\/j.amsu.2018.01.002_bib76","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ijrobp.2007.11.046","article-title":"High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions","volume":"71","author":"Yamada","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.amsu.2018.01.002_bib77","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s11547-008-0314-1","article-title":"Cementoplasty in the management of painful extraspinal bone metastases: our experience","volume":"113","author":"Basile","year":"2008","journal-title":"La Radiologia medica"},{"key":"10.1016\/j.amsu.2018.01.002_bib78","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/BLO.0b013e3180616594","article-title":"Radiotherapy to bone has utility in multifocal metastatic renal carcinoma","volume":"459","author":"Reichel","year":"2007","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"10","key":"10.1016\/j.amsu.2018.01.002_bib79","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.amsu.2018.01.002_bib80","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/00004728-199411000-00016","article-title":"Injection of alcohol into bone metastases under CT guidance","volume":"18","author":"Gangi","year":"1994","journal-title":"J. Comput. Assist. Tomogr."},{"issue":"2","key":"10.1016\/j.amsu.2018.01.002_bib81","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1148\/radiol.2412051247","article-title":"Painful metastases involving bone: percutaneous image-guided cryoablation\u2013prospective trial interim analysis","volume":"241","author":"Callstrom","year":"2006","journal-title":"Radiology"},{"key":"10.1016\/j.amsu.2018.01.002_bib82","first-page":"S69","volume":"vol. 25","author":"Simon","year":"2005"},{"issue":"5","key":"10.1016\/j.amsu.2018.01.002_bib83","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s00270-004-0208-0","article-title":"Radiofrequency ablation therapy combined with cementoplasty for painful bone metastases: initial experience","volume":"28","author":"Toyota","year":"2005","journal-title":"Cardiovas. Intervent. Radiol."},{"issue":"1","key":"10.1016\/j.amsu.2018.01.002_bib84","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"}],"container-title":["Annals of Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2049080118300062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2049080118300062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.amsu.2018.01.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:24:06Z","timestamp":1789647846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.amsu.2018.01.002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":84,"alternative-id":["S2049080118300062"],"URL":"https:\/\/doi.org\/10.1016\/j.amsu.2018.01.002","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skeletal metastasis in renal cell carcinoma: A review","name":"articletitle","label":"Article Title"},{"value":"Annals of Medicine and Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amsu.2018.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.","name":"copyright","label":"Copyright"}]}}